Pharmacogenomics is the study of how genetic variation affects individual responses to drugs, supplements, and dietary compounds. It explains why the same dose of caffeine keeps one person wired for 12 hours while another barely notices it, why folic acid helps most people but is poorly utilized by ~15% of the population, and why some people get severe side effects from medications that others tolerate easily.

The key players are single nucleotide polymorphisms (SNPs) — single-letter variations in your DNA sequence that alter the function of specific proteins. Most SNPs have minimal impact individually, but certain SNPs in metabolic enzymes, transporters, and receptors can dramatically change how you process specific compounds.

The most actionable pharmacogenomic information falls into three categories:

1. Drug metabolism enzymes (CYP450 family): Determine how fast you activate or clear medications and supplements from your body.

2. Methylation cycle enzymes (MTHFR, COMT, MAO, CBS): Determine how efficiently you process folate, manage catecholamines, and regulate sulfur metabolism.

3. Nutrient metabolism variants (VDR, FUT2, BCMO1): Determine your individual requirements for specific vitamins and nutrients.

What makes pharmacogenomics genuinely useful (vs marketing): the actionable variants are well-studied, the mechanisms are understood, and the interventions are specific. MTHFR C677T → use methylfolate instead of folic acid. CYP1A2 slow metabolizer → limit caffeine after noon. VDR variants → may need higher vitamin D doses. These are concrete, evidence-based personalizations — not the vague "eat for your genes" marketing that characterizes most consumer nutrigenomics.

The cytochrome P450 (CYP) enzyme family metabolizes approximately 75% of all drugs, plus countless dietary compounds, hormones, and environmental toxins. Genetic variants in CYP genes create distinct metabolizer phenotypes:

Poor metabolizer (PM): Enzyme has little or no activity. Drugs metabolized by this enzyme accumulate to higher levels, last longer, and produce stronger effects. Risk of toxicity at standard doses.

Intermediate metabolizer (IM): Reduced enzyme activity. Effects between PM and normal.

Extensive/Normal metabolizer (EM/NM): Standard enzyme activity. The population "average" that drug doses are designed for.

Ultra-rapid metabolizer (UM): Increased enzyme activity. Drugs are cleared faster, producing weaker or shorter effects. Standard doses may be insufficient.

Key CYP enzymes and practical implications:

CYP1A2: Metabolizes caffeine, melatonin, and some medications. Slow metabolizers (AA genotype at rs762551): caffeine has a half-life of 8+ hours instead of the typical 5. Afternoon coffee disrupts sleep. Melatonin may need lower doses. Fast metabolizers (AC/CC): can tolerate caffeine later in the day. IMPORTANTLY: CYP1A2 slow metabolizers who drink 3+ cups of coffee daily have INCREASED cardiovascular risk, while fast metabolizers show reduced risk — the same behavior has opposite health outcomes based on genotype.

CYP2D6: Metabolizes ~25% of all drugs including codeine, tramadol, many antidepressants, and tamoxifen. Poor metabolizers: codeine provides no pain relief (it's a prodrug that requires CYP2D6 conversion to morphine). Ultra-rapid metabolizers: codeine conversion to morphine is dangerously fast — risk of respiratory depression, especially in children (FDA black box warning).

CYP3A4: The workhorse enzyme — metabolizes ~50% of all drugs. Notably inhibited by grapefruit juice (furanocoumarins in grapefruit irreversibly inactivate CYP3A4, causing drug levels to spike). Also inhibited by St. John's Wort (but via enzyme INDUCTION, which reduces drug levels — the opposite effect). Any supplement protocol should be cross-checked against CYP3A4 substrates if the person takes medications.

CYP2C19: Metabolizes PPIs (omeprazole), some antidepressants, and clopidogrel (blood thinner). Poor metabolizers: PPIs last longer and are more effective. Clopidogrel doesn't work (it's a prodrug requiring CYP2C19 activation) — this has caused treatment failures in cardiovascular patients.

The methylation cycle is a biochemical pathway that transfers methyl groups (CH3) to DNA, proteins, neurotransmitters, and other molecules. It's essential for: DNA repair and gene expression regulation (epigenetics), neurotransmitter synthesis and degradation, detoxification (phase II liver metabolism), immune function, and energy production.

MTHFR (methylenetetrahydrofolate reductase): Converts dietary folate to methylfolate (5-MTHF), the active form used in the methylation cycle. Two common variants:

C677T: Homozygous TT (~10-15% of population, varies by ethnicity) reduces enzyme activity to ~30% of normal. Heterozygous CT (~40%) reduces to ~65%. Impact: reduced methylfolate production → elevated homocysteine (cardiovascular risk marker) → impaired methylation capacity. Intervention: take methylfolate (5-MTHF) instead of folic acid. Folic acid requires MTHFR to convert — if the enzyme is impaired, folic acid accumulates unmetabolized.

A1298C: Affects a different region of the enzyme. Mild effect alone but compound heterozygosity (one C677T + one A1298C) can significantly reduce function.

COMT (catechol-O-methyltransferase): Degrades catecholamines (dopamine, norepinephrine, epinephrine) and catechol estrogens. The Val158Met polymorphism creates two phenotypes:

Val/Val (fast COMT): Rapid catecholamine degradation. Tends toward lower baseline dopamine. May need more stimulation to feel motivated. More stress-resilient (clears stress hormones quickly) but potentially lower pain tolerance.

Met/Met (slow COMT): Slow catecholamine degradation. Higher baseline dopamine. May be more focused and creative but more susceptible to anxiety under stress (catecholamines accumulate). More sensitive to caffeine, stimulants, and stress. Higher pain tolerance but potentially more anxious.

MAO (monoamine oxidase): Another catecholamine degradation enzyme. MAO-A variants affect serotonin and norepinephrine metabolism. Low-activity MAO-A may predispose to higher serotonin sensitivity (more reactive to SSRIs, potentially more mood variability).

Practical framework: methylation genetics inform supplement FORM selection (methylfolate vs folic acid, methylcobalamin vs cyanocobalamin) and lifestyle strategies (slow COMT → manage stimulant intake, support with magnesium; fast COMT → may tolerate stimulants well but consider dopamine support).

Nutrigenomics — how genetic variants affect nutrient metabolism — has genuine science behind it AND a massive marketing problem. Here's how to separate signal from noise:

Genuinely actionable variants (clear mechanism, validated intervention):

VDR (vitamin D receptor): Multiple variants affect how efficiently your cells respond to vitamin D. Some people need significantly higher serum levels to achieve the same intracellular effect. Combined with CYP2R1 variants (vitamin D activation enzyme), this explains why vitamin D supplementation needs vary 3-5x between individuals. Always dose to blood level, not to a standard dose.

FUT2: Determines "secretor status." Non-secretors (~20% of population) have altered gut microbiome composition and impaired vitamin B12 absorption. May need higher B12 doses or methylcobalamin specifically.

BCMO1: Converts beta-carotene to vitamin A (retinol). Some variants reduce conversion efficiency by 50-70%. People with these variants cannot rely on plant sources (carrots, sweet potatoes) for vitamin A — they need preformed retinol from animal sources or supplements.

HFE: Hemochromatosis gene. Carriers (and especially homozygotes) absorb excess iron — should NOT supplement iron and should monitor ferritin. Relatively common: 1 in 200-300 people of Northern European descent are homozygous.

Marketing-overhyped nutrigenomics:

"Eat for your DNA type" programs: Most use loosely associated SNPs to generate personalized diet plans. The effect sizes of individual dietary SNPs are tiny — your overall dietary pattern matters far more than any individual genetic variant. A whole food diet is optimal regardless of genotype.

"Genetic weight loss" programs: While genetics influence body composition tendencies, no genetic test reliably predicts which specific diet (low-carb vs low-fat) will produce better results for you. The strongest predictor of diet success is adherence — which is behavioral, not genetic.

"Genetic fitness" testing: While some variants influence fast-twitch vs slow-twitch fiber proportion and injury risk, the practical training implications are minimal for non-elite athletes. Train based on your response to training, not your genotype.